Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)
Not Applicable
Recruiting
- Conditions
- Melanoma
- Interventions
- Procedure: Personalized Circulating DNA follow-up
- Registration Number
- NCT04866680
- Lead Sponsor
- Institut de Cancérologie de Lorraine
- Brief Summary
PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 165
Inclusion Criteria
- locally advanced, operable melanoma
- treated by immunotherapy or anti-BRAF and anti-MEK targeted therapies (stage IIIb, IIIc) or exclusive immunotherapy (stage IV) in an adjuvant situation.
Exclusion Criteria
- second cancer
- woman who is pregnant, likely to be pregnant or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Personalized Circulating DNA follow-up Personalized Circulating DNA follow-up FFPE tissue sample + blood sample (20ml)
- Primary Outcome Measures
Name Time Method Studying the tumor molecular abnormalities resulting from circulating tumor DNA (ctDNA) to predict the resistance to treatment 24 months Quantity of ctDNA / Resistance to treatment defined as a change in treatment decided during staff meeting
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
Institut Godinot
🇫🇷Reims, France
CHU Jean Minjoz
🇫🇷Besançon, France
CGFL
🇫🇷Dijon, France
Chu Dijon
🇫🇷Dijon, France
Chru Lille
🇫🇷Lille, France
Ghr Mulhouse Sud Alsace
🇫🇷Mulhouse, France
Institut de Cancerologie de Lorraine
🇫🇷Vandœuvre-lès-Nancy, France
Chru Nancy
🇫🇷Vandœuvre-lès-Nancy, France